Provide a valuable resource to your clients or customers by linking to this resource page. Just place the following link on your website.
Endari is a prescription oral powder containing L-glutamine. It is approved to reduce acute complications of sickle cell disease in adults and pediatric patients age 5 and older. Each packet contains 5 g of L-glutamine and is mixed with a beverage or soft food immediately before ingestion.
read more about endari ...The mechanism of L-glutamine in sickle cell disease is not fully defined. Oxidative stress contributes to sickle red blood cell damage. In vivo analyses described in the labeling showed improved NAD redox potential after L-glutamine supplementation. This redox pathway is linked to protection against oxidative damage in red blood cells.
Endari is used in adults and children age 5 and older with sickle cell disease to reduce acute disease complications. Safety and efficacy have not been established in children younger than 5. The medicine is taken orally twice daily using a body-weight-based dose.
Patients weighing less than 30 kg take 5 g twice daily. Those weighing 30 kg to 65 kg take 10 g twice daily, and those above 65 kg take 15 g twice daily. Each dose is mixed with 8 oz of a cold or room-temperature beverage or 4 oz to 6 oz of food.
Current labeling lists constipation, nausea, headache, abdominal pain, cough, pain in an extremity, back pain, and chest pain among the most common adverse reactions. No contraindications are listed in the prescribing information. Pregnancy and breastfeeding data are limited, so treatment decisions consider individual clinical circumstances.
Endari reduces acute complications of sickle cell disease in adults and children age 5 and older.
Endari is taken twice daily using a dose based on body weight.
Each packet contains 5 g of L-glutamine oral powder.
No. The labeled dose is based on body weight and ranges from 5 g to 15 g per dose twice daily.
A Phase 3 Trial of L-Glutamine in Sickle Cell Disease. https://pubmed.ncbi.nlm.nih.gov/30021096/. Date Accessed September 29, 2026.
Endari (L-Glutamine) Oral Powder Supplement Approval. https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/208587Orig1s004ltr.pdf. Date Accessed September 29, 2026.
ENDARI (L-Glutamine Oral Powder) Prescribing Information. https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=d5a783f4-12ef-4326-8faa-40018e45ba3b. Date Accessed September 29, 2026.
FDA Approves New Treatment for Sickle Cell Disease. https://www.fda.gov/news-events/press-announcements/fda-approves-new-treatment-sickle-cell-disease. Date Accessed September 29, 2026.
L-Glutamine: MedlinePlus Drug Information. https://medlineplus.gov/druginfo/meds/a617035.html. Date Accessed September 29, 2026.